Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Tradjenta (linagliptin) ## Overview Linagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing incretin levels, which reduces glucagon secretion, improves insulin sensitivity, and slows gastric emptying. ## Primary Indications Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ## Adult Dosing The recommended dose of linagliptin is 5 mg orally once daily. ## Pediatric Dosing Dosing for pediatric patients has not been established. ## Dose Adjustments No dose adjustment is required for patients with renal impairment or hepatic impairment. ## Contraindications * Hypersensitivity to linagliptin or any excipients in the formulation. ## Adverse Effects * **Common:** Nasopharyngitis, diarrhea, cough. * **Serious:** Hypoglycemia (especially when used in combination with sulfonylureas or insulin), severe and disabling arthralgia (joint pain), angioedema, Stevens-Johnson syndrome, pancreatitis. ## Key Drug Interactions * **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort):** May decrease linagliptin exposure and efficacy. Concurrent use is not recommended. * **Sulfonylureas and Insulin:** Increased risk of hypoglycemia. Dose reduction of the sulfonylurea or insulin may be considered. ## Monitoring * **Blood Glucose:** Monitor glycemic control regularly. * **Renal Function:** Baseline and periodic monitoring is not required due to lack of dose adjustment based on renal function. * **Pancreatic Enzymes:** Monitor for signs and symptoms of pancreatitis (e.g., persistent severe abdominal pain, with or without vomiting). * **Signs of Hypersensitivity/Angioedema:** Monitor for signs and symptoms. ## Clinical Pearls * Linagliptin is primarily eliminated unchanged via the bile and gut, and to a lesser extent, via the kidneys, hence no dose adjustment is needed in renal or hepatic impairment. * It has no known drug interactions mediated by CYP450 enzymes. * Consider the increased risk of hypoglycemia when used with insulin or sulfonylureas. * Educate patients about the signs and symptoms of pancreatitis and severe allergic reactions. *** *Disclaimer: This information is intended for healthcare professionals and should not substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines for complete details.*